Subscribe


PD breaking news – ACCC to appeal atorvastatin decision

Federal Court dismissed anti-competitive conduct case in February. 

The Australian Competition and Consumer Commission (ACCC) has filed a Notice to Appeal for the Federal Court’s decision to dismiss its anti-competitive conduct case against Pfizer.

The ACCC allegations related to offers made to pharmacies in early 2012 for the supply of Lipitor and Pfizer’s generic atorvastatin product, with the ACCC alleging Pfizer had misused its “substantial market power” and engaged in exclusive dealing conduct for the purpose of substantially lessening competition.

The Federal Court dismissed the case, saying that while Pfizer had taken advantage of its market power with the alleged conduct, this power was no longer substantial at the time of the offers, and that the ACCC had not established that Pfizer had engaged in this conduct to deter or prevent competitive conduct (PD 26 Feb).

ACCC chairman Rod Sims said cases involving allegations of misuse of market power and anti-competitive practices would always be a priority for the organisation.

“It is therefore important that the ACCC seeks clarity from the Full Court on issues of market power and anti-competitive purpose, such as those raised by this case.”

For more, see tomorrow’s Pharmacy Daily.


The above Breaking News Alert was sent to Pharmacy Daily subscribers on 18 Mar 15

Make a comment...



Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.

Register for Pharmacy Daily trial subscription

To sign up for a free subscription, click on the button at right.

Click here to see a sample issue of Pharmacy Daily.

Click here for more information on subscriptions.

Alternatively, you can search our site via the search box on the right hand side of the page, or find other content below.

Recent Pharmacy Daily articles

20 Feb

Guild Update 20 Feb 18 - WORKPLACE resources GUILD Members may be interested ...


20 Feb

Dispensary Corner 20 Feb 18 - SUFFERERS of conditions like irritable bowel syndrome ...


20 Feb

Meds reconciliation - HIGHER accuracy of complex medication reconciliation can ...


20 Feb

Metformin XR recall - APOTEX, in consultation with the TGA, is ...


20 Feb

Arthrem safe - FOLLOWING the NZ Medsafe "potential risk" alert ...


20 Feb

Mundipharma buys Tolmar for Eligard(R) - FOLLOWING several months of comprehensive due diligence ...


20 Feb

Precision medicine - THE future of precision medicine in Australia ...


20 Feb

Dispensing error decriminalisation - NEW legislation to protect community pharmacists in ...


20 Feb

TGA CM advertising debate - BOTH science and civil society organisations have ...


20 Feb

Pharmacy training offers - THE Pharmaceutical Society of Australia (PSA) has ...


19 Feb

Weekly Comment 19 Feb 18: Promoting your personal brand - THIS week's contributor is Heidi Dariz, General ...


19 Feb

Dispensary Corner 19 Feb 18 - PEOPLE can remain very loyal to their ...


19 Feb

Arthrem safety alert - NEW Zealand Medicines and Medical Devices Safety ...


19 Feb

Roche to buy Flatiron - ROCHE has announced it has signed a ...


19 Feb

Gannon slams vaping - AMA president Michael Gannon has highlighted the ...


19 Feb

FDA guidance x seven - THE US Food and Drug Administration (FDA) ...


19 Feb

Potent new flu vaccine - A NEW high dose influenza vaccine will ...


19 Feb

Schulze WA POTY - FORMER PDL chairman and current chairman of ...


19 Feb

WA Guild elections - NOMINATIONS are open for the election of ...


19 Feb

‘Pharmacy first’ says NHS - PARENTS of young children with minor illnesses ...



Show Pharmacy Daily items by month: